FT500
Science Translational Medicine 2020; 12(568).
iPSC-Derived NK Cells Maintain High Cytotoxicity and Enhance In Vivo Tumor Control in Concert with T Cells and Anti–PD-1 TherapyJ Clin Invest. 2018; 128(10): 4654–4668.
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockadeBritish Journal of Cancer. 2018; 118: 9–16.
Mechanisms of resistance to immune checkpoint inhibitorsNature Communications. 2017; 8: 1136.
Resistance to checkpoint blockade therapy through inactivation of antigen presentationFT516
2021 ASH Abstract
Phase I Study of FT516, an Off-the-Shelf, iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed / Refractory B-Cell LymphomaBlood. 2020; 135 (6): 399–410.
Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activityFT536
2021 SITC Abstract
FT536 Path to IND: Ubiquitous targeting of solid tumors with an off-the-shelf, first-of-kind MICA/B-specific CAR-iNK cellular immunotherapyCancer Immunol Res 2020; 8:769–80.
Inhibition of MICA and MICB Shedding Elicits NK-Cell–Mediated Immunity against Tumors Resistant to Cytotoxic T CellsFT596
New England Journal of Medicine. 2020; 382: 545–53.
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid TumorsFT538
Cancer Stem Cell Publication
Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy2021 SITC Abstract
Off-the-shelf, engineered iPSC-derived NK cells mediate potent cytotoxic activity against primary glioblastoma cells and promote durable long-term survival in vivo2020 ASH Poster Presentation – Manufacturing
cGMP Mass Production of FT538, a First of Kind, Off the Shelf, Multiplexed Engineered Natural Killer Cell Cancer Immunotherapy Derived from a Clonal Master Induced Pluripotent Stem Cell Line2020 ASH Poster Presentation – Clinical
A Phase I Study of FT538, a First of Kind, Off the Shelf, Multiplexed Engineered, iPSC Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple MyelomaFT576
FT819
2021 ASH Abstract
Clinical Manufacture of FT819: Use of a Clonal Multiplexed-Engineered Master Induced Pluripotent Stem Cell Line to Mass Produce Off-the-Shelf CAR T-Cell Therapy2019 ASH Abstract
FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical TrialNature Medicine. 2019; 25: 82–88.
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potencyNature. 2017; 543: 113–117.
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejectioniPSC Product Platform
